Kyowa Hakko USA Inc.

Kyowa Hakko’s Pharmaceutical Company mission is to develop biopharmaceuticals for treatment of cancer and allergies. Key R&D activities for creation of antibody drug technologies including commercial production for genome drug discovery. In line with Kyowa’s expanding Pharmaceutical operations, Kyowa Hakko is giving priority to development in Europe and the United States for products in its pipeline of original drugs. R&D Pipeline drugs include anticancer, antiallergic, CNS, Cardio, Urology, and others. All are in various phases in the Japan and in the US/Europe/Canada.
Kyowa Hakko’s Biochemicals Company is focused on fine chemicals such as amino acids and nucleic acids for pharmaceuticals, nutrition and industrial uses. Furthermore developing new functionality and new application for new products with Kyowa Hakko’s oligosaccharide and peptide manufacturing capabilities.

Activity:

- Licensing & Business Development
- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- API / chemicals
- Bio
- Cosmoceuticals
- Enzymes
- FP (finished products)
- Pharmaceuticals / Therapeutics
- Nutritionals / Vitamins
- Prescription drugs (Rx)

Therapeutic targets:

- Allergy
- Cancer
- Cardiovascular
- Central nervous system
- Men's Health
- Ophthalmology
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: Japan

b. Continent(s) active: Asia , North America , Europe , Central/South America

c. Countries active: Japan, USA, Germany, Italy, China, Mexico, UK, Hungary, Singapore, Thailand, Malaysia

Corporate data:

Number of Employees: 7,300

Turnover:

Amount:	Year:	Currency:
3,031,558,000.	2001	US Dollar

Year founded: 1949

Stock options:

	Symbol	Exchange
1	4151	Tokyo, Osaka, Nagoya, Fukouka, Sapporo